Risk-based screening is transforming breast cancer prevention. However, a new analysis of the WISDOM study reveals that pathogenic variant testing plays a more critical role than previously realized. Researchers found that traditional clinical risk factors and polygenic risk scores often fail to identify high-risk individuals. Consequently, many women who require intensive screening might be overlooked without genetic data.

Study Findings and Risk Discrepancies

The secondary analysis included 712 women who tested positive for pathogenic variants (PVs). Surprisingly, there was very little overlap between clinical risk-based assignments and genetic findings. Among high-penetrance PV carriers, clinical and polygenic risk scores alone would have correctly identified less than 1% for high-risk screening. Furthermore, clinical plus polygenic risk models would have advised over 60% of younger carriers to defer screening until age 50. Therefore, clinical tools like the Breast Cancer Surveillance Consortium (BCSC) model are not sufficient for high-risk detection.

Enhancing Precision with Pathogenic Variant Testing

Personalized screening strategies aim to balance safety with efficiency. In this cohort, pathogenic variant testing identified subsets of high-risk women that other models missed entirely. Notably, 30% of PV carriers reported no significant family history. This finding challenges the current reliance on family history as a gateway for genetic referral. By incorporating population-based genetic testing, clinicians can better stratify patients. This approach ensures that those with high-penetrance mutations receive essential semi-annual imaging, while lower-risk individuals avoid unnecessary procedures.

FAQs

How does pathogenic variant testing change screening intervals?

Individuals with high-penetrance mutations usually require alternating mammography and MRI every six months. Standard clinical models often recommend biennial mammography for these same patients, which could lead to delayed diagnoses.

Can polygenic risk scores replace traditional genetic testing?

No, the study shows that polygenic risk scores and pathogenic variant testing identify different groups of at-risk women. They are complementary tools rather than replacements for one another.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals should exercise clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Shieh Y et al. Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study. JAMA Oncol. 2026 May 31. doi: 10.1001/jamaoncol.2026.2091. PMID: 42218736.


2. UCI Health. WISDOM Study results published in JAMA and JAMA Internal Medicine. February 2026.


3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Version 1.2026.